Changing Oncology Treatment Paradigms in the COVID-19 Pandemic

Lou, Emil; Subramanian, Subbaya

doi:10.1016/j.clcc.2020.05.002

Cited by 3 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Results: Clinical Questions and Statementsmentioning

confidence: 99%

Section: Results: Clinical Questions and Statementsmentioning

confidence: 99%

“…A triage system involving the oncology team must be set up to ensure a fair assessment of cancer patients in the event of admission to the ICU and in case of worsening of patients' clinical conditions while in the ICU. 55,56 During the COVID-19 pandemic, has the riskebenefit profile for including an individual patient in a clinical trial changed?…”

Section: Should Tkis Be Suspended During a Patient's Active Sars-cov-2 Infection?mentioning

confidence: 99%

“…Regardless, adaptations to the pandemic should not change the processes and timelines of safety reporting and pharmacovigilance declaration, which should be done completely and promptly even when using remote methods of patient assessment. 56,57 Patient-reported outcomes merit special attention as clinical trial end points. Although remote patient monitoring may not change the self-reporting ability of patients, measures such as QoL and physical functioning are likely to be impacted by the social distancing and other measures in response to the pandemic.…”

Section: Should Tkis Be Suspended During a Patient's Active Sars-cov-2 Infection?mentioning

confidence: 99%

See 3 more Smart Citations

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Curigliano¹,

Banerjee²,

Cervantes³

et al. 2020

Annals of Oncology

272

279

View full text Add to dashboard Cite

We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed on 28 consensus statements that can be used to overcome many of the clinical and technical areas of uncertainty ranging from diagnosis to therapeutic planning and treatment during the COVID-19 pandemic.

show abstract

Section: Results: Clinical Questions and Statementsmentioning

confidence: 99%

Section: Results: Clinical Questions and Statementsmentioning

confidence: 99%

Section: Should Tkis Be Suspended During a Patient's Active Sars-cov-2 Infection?mentioning

confidence: 99%

Section: Should Tkis Be Suspended During a Patient's Active Sars-cov-2 Infection?mentioning

confidence: 99%

See 2 more Smart Citations

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Curigliano¹,

Banerjee²,

Cervantes³

et al. 2020

Annals of Oncology

272

279

View full text Add to dashboard Cite

show abstract

“…Strategies to enhance collaboration in the oncology sector include: Supporting continued and improved sustainability of national and international collaborations for sharing of data and information, including collaboration between state and territory cancer registries, and government agencies, to enable timely access to cancer data for clinicians and researchers. Identifying opportunities to further leverage collaboration in the oncology sector, such as incorporating mathematical oncology and bioengineering expertise into clinical trial design, health services research, and developing decision‐making tools to more effectively diagnose and manage cancer 50 Encouraging health practitioner and patient engagement in collaboration across the oncology sector. …”

Section: Recommendationsmentioning

confidence: 99%

Cancer Australia consensus statement on COVID‐19 and cancer care: embedding high value changes in practice

Milch

Wang

Vartanian

et al. 2021

Medical Journal of Australia

View full text Add to dashboard Cite

Introduction Driven by the need to reduce risk of SARS‐CoV‐2 infection and optimise use of health system resources, while maximising patient outcomes, the COVID‐19 pandemic has prompted unprecedented changes in cancer care. Some new or modified health care practices adopted during the pandemic will be of long term value in improving the quality and resilience of cancer care in Australia and internationally. The Cancer Australia consensus statement is intended to guide and enhance the delivery of cancer care during the pandemic and in a post‐pandemic environment. This article summarises the full statement, which is available at https://www.canceraustralia.gov.au/covid-19/covid-19-recovery-implications-cancer-care. Main recommendations The statement is informed by a desktop literature review and input from cancer experts and consumers at a virtual roundtable, held in July 2020, on key elements of cancer care that changed during the pandemic. It describes targeted strategies (at system, service, practitioner and patient levels) to retain, enhance and embed high value changes in practice. Principal strategies include: implementing innovative models of care that are digitally enabled and underpinned by clear governance, policies and procedures to guide best practice cancer care; enabling health professionals to deliver evidence‐based best practice and coordinated, person‐centred cancer care; and empowering patients to improve health literacy and enhancing their ability to engage in informed, shared decision making. Changes in management as a result of this statement Widespread adoption of high value health care practices across all levels of the cancer control sector will be of considerable benefit to the delivery of optimal cancer care into the future.

show abstract

COVID-19 in Patients with Different Hematological Malignancies: Treatment Strategy and Outcome: An Iraqi Experience

Naji,

Barwari,

Al-Khero

et al. 2024

Jordan Med. J.

View full text Add to dashboard Cite

Background: Patients with hematological malignancies may have higher rates of morbidity and mortality due to SARS-COVID-19 than those in the general population. Objectives: To evaluate the outcome of SARS-COVID-19 in patients with different hematological malignancies undergoing active or modified therapy. Settings: This was a retrospective cohort, multicenter study conducted on 167 patients diagnosed with SARS-COVID-19. The selected patients had been diagnosed with different hematological malignancies and had received treatment (chemotherapy or immunosuppressive). The study was carried out in different centers across Iraq between 1 December 2020 and 1 December 2021. Patients and Methods: This study was conducted in seven hematology centers across Iraq with 167 patients; of these, this study showed that 88 (52.7%) were males and 79 (47.3%) were females (mean age 51.9 ± 18.3 years). All patients had had a COVID-19 infection confirmed through RNA-specific fragments by real-time reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharyngeal swab specimens, and by computed tomography (CT) of the chest. Demographic data were obtained from patient files, which included the type of hematological malignancy, treatment (chemotherapy, immunotherapy, supportive), severity of COVID-19, modification of treatment and disease outcome for patients, whether alive or not. Patients identified as having benign or non-hematological malignancies were excluded. Results: The treatment protocol was modified in 124 patients (74.3%), while 43 patients (25.7%) continued on the same protocol. Regarding treatment outcomes, 77.2% of patients were alive at the end of the study and 22.8% had died. The survival of COVID-19 patients did not change significantly when the treatment protocol was modified compared to those who continued on treatment as per protocol. The death rate was significantly higher among patients with severe disease compared to those with mild and moderate disease (61.4% v. 0% and 5.0%, respectively) (p<0.001). Conclusions: The management of patients with hematological malignancies during the COVID-19 pandemic may be challenging, with higher mortality in patients with concurrent hematological malignancies and COVID-19. The survival of COVID-19 patients did not change significantly when treatment was modified. Age groups, sex, type of hematological malignancy, and disease status did not affect the survival of these patients. The death rate was significantly higher among patients with hematological malignancies and severe COVID-19 compared with mild or moderate disease.

show abstract

Changing Oncology Treatment Paradigms in the COVID-19 Pandemic

Cited by 3 publications

References 18 publications

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Cancer Australia consensus statement on COVID‐19 and cancer care: embedding high value changes in practice

COVID-19 in Patients with Different Hematological Malignancies: Treatment Strategy and Outcome: An Iraqi Experience

Contact Info

Product

Resources

About